NanoPhagix is developing a unique therapeutic delivery system that lets doctors treat the major cause of heart attacks directly at the source.
- NanoPhagix, LLC was founded June 22, 2015
- Highly experienced executive management team
- Targeted therapeutic delivery system with the potential to prevent a heart attack at its source
- Significant market potential with multiple unmet market needs
- Company plans to commercialize multiple products with initial focus on vascular inflammation
A Potential Breakthrough Therapy
NanoPhagix has combined the delivery mechanism of a nanoparticulate imaging agent with rapamycin to deliver a potent anti‑inflammatory directly to multiple sites of vascular inflammation. This unique formulation allows for selective delivery to unstable plaque areas and enables safer targeting of the drug to the sites of need. Rapamycin is an approved anti‑inflammatory drug previously shown to have a wide variety of cardiovascular benefits.
Provides targeted delivery of rapamycin in a host of different inflammatory medical conditions.
NanoPhagix will focus initially on cardiovascular disease...One of a host of high‑value target markets
- Primary indication: Acute Coronary Syndrome
- Secondary intervention following a 1st heart attack
- Initially IV will be the primary method of administration but a local injection is also planned
- NanoPhagix expects to be able to reduce the cost of Phase II clinical trials and shorten development time because substantial data already exists from clinical experience with diatrizoic acid (the stabilizer) and rapamycin (the therapeutic), both of which are FDA approved and have been in commercial use for at least 15 years
Executing the Plan: The Team
Chief Executive Officer & Co‑founder
Don has helped more than 100 early-stage therapeutics, diagnostics, medical device, vaccine and mobile health companies get to the next level. His career spans pharmaceuticals, consumer advertising, magazine publishing, market research, sports marketing, strategic business development and corporate acquisitions.
Prior to co‑founding NanoPhagix, Don founded and ran several early-stage companies and two non-profit associations: among them are NanoScan Imaging and The Pharmaceutical Consulting Consortium International (PCCI). He formed PodFundr as an extension of PCCI to give institutional and strategic investors, VCs, angel groups and family offices ground-floor access to more early-stage investment-grade deals in more healthcare market segments than are typically available through traditional sources. His acquisition efforts on behalf of Hillenbrand Industries resulted in their $100 million purchase of Mediq.
Before becoming an entrepreneur, Don served as a top executive in a $30 million ad agency whose clients included SmithKline, Wyeth, and other large pharmaceutical clients. Don began his marketing career at Smith Kline & French Laboratories, where he worked in a variety of therapeutic areas, including anti‑hypertensives, diuretics, major tranquilizers, and psychiatric products.
Steven Adelman, Ph.D.
Chief Scientific Officer & Co‑founder
Dr. Adelman has more than 25 years experience in drug discovery and drug development. Prior to founding Vascular Strategies LLC in 2006, Dr. Adelman lead several initiatives at Wyeth Pharmaceuticals, holding among other positions: Senior Director, Cardiovascular and Metabolic Disease Discovery Research; Senior Director, Atherosclerosis CV/Women's Health Research; and Director, Vascular Diseases, Cardiovascular and Metabolic Diseases Research; Associate Director, Vascular Diseases Cardiovascular and Metabolic Diseases Research Division, and Principal Scientist; Cardiovascular and Metabolic Diseases Research Division. His responsibilities included directing up to 50 scientists, PhDs, and technical staff focused on identifying and validating drug discovery targets, developing programs for discovery of lead compounds (small molecules and biologics), advancing compounds to clinical development, and use of translational biomarkers.
As Senior Director of Cardiovascular Research at Wyeth, he worked extensively on rapamycin (sirolimus, Rapamune®), including its approval by the FDA and European regulatory agencies for transplant indications and its incorporation on the Cypher® Sirolimus-eluting Coronary Stent, the first successful drug-eluting coronary stent, which was then a breakthrough technology.
Dr. Adelman holds a PhD in biochemistry from the Medical College of Pennsylvania/ Allegheny University, Philadelphia, and an MA in Cell and Molecular Biology and a BA in Biology from the State University of New York at Buffalo.
Some of his honors and memberships include: Fellow American Heart Association; Golden Heart Member, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Basic Sciences Council, Functional Genomics and Translational Biology Interdisciplinary Working Group of AHA, and International Atherosclerosis Society; Research Fellow, Wake Forest University, Specialized Center of Research in Arteriosclerosis (SCOR) Winston-Salem, NC. He has written or co‑authored more than 75 medical articles and abstracts, and individually or with others, holds 12 medical patents.
Peter van der Kam
Chief Operating Officer & Co‑founder
Mr. van der Kam served as a senior marketing and operations executive at Merck and later directed Wyeth's European operations. Peter's pharmaceutical career began with CIBA-Geigy in Australia, where he served as Product Manager of anti-inflammatory products. He later joined Merck in Spain as Manager for New Products where he doubled the Affiliate's sales following the launch of anti-inflammatory Clinoril and beta-blocker Blocadren. At Merck he was appointed Director of Marketing in Venezuela. Peter later returned to Merck headquarters in the US to join the launch team responsible for the international introduction of Enalapril. Peter moved to Wyeth International in 1983 as Director for Cardiovasculars, then Deputy General Manager in Spain, followed by Group Director European Operations.
Peter helped Don Skerrett found and grow the Pharmaceutical Consulting Consortium International, a non‑profit association focused on helping life sciences startups reach their next level of development. He has consulted internationally with companies like LaviPharm and also served with the International Executive Service Corps in Amman where he restructured Dar Al Dawa, a regional pharmaceutical company in the Middle East. Peter joined NanoScan as COO in 2010 and is a founding member of NanoPhagix, LLC.
This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements give our current expectations or forecasts and use words such as "anticipate," "estimate," "expect," "believe," and other words of similar meaning. Any or all of the forward-looking statements in this presentation may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties including but not limited to, the efficacy of our product candidates, their efficacy at acceptable dosage levels, the ability to raise capital when needed and on reasonable terms, projections of potential commercial sales of company products, the results and progress of clinical trials, developing the necessary manufacturing processes and gaining all necessary regulatory approvals, both in the United States and internationally. Consequently, no forward-looking statement can be guaranteed and actual results may differ materially. However, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995.
About Easter Island and Rapamycin
Rapamycin was initially discovered as an antifungal metabolite produced by Streptomyces hygroscopicus from a soil sample of Easter Island (also known as Rapa Nui). Rapamycin has been found to possess immunosuppressive and anti-proliferative properties in mammalian cells.
The photograph that serves as the background for the graphic at the top of each page is "Sunrise at Easter Island" by Anne Dirske, a travel photographer. The photo is of Ahu Tongariki, the largest Moai site of Easter Island. It has 15 moai lined up and includes the largest moai ever erected on the island. The original photograph may be viewed at http://www.annedirkse.com/2013/03/20/sunrise-at-ahu-tongariki-easter-island-chile/. Ms. Dirske has a Facebook page and a flickr page where you can view more of her excellent photography.